Seeking Alpha

Cantor Fitzgerald initiates TrovaGene (TROV) at Buy with a $10 price target citing the...

Cantor Fitzgerald initiates TrovaGene (TROV) at Buy with a $10 price target citing the likelihood that "compelling early data associated with the company's nucleic acid assays … will increase interest among leading cancer centers in further exploring the clinical utility" of complementing or replacing tumor tissue biopsies.
Comments (1)
  • GetOffMyLawn
    , contributor
    Comments (16) | Send Message
     
    Myriad case also implies 'transrenal DNA' - another natural occurrence - can also not be patented.
    16 Jul 2013, 01:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector